MetaVia to Showcase DA-1726 Dual Agonist Phase 1 Data at Barcelona EASL Congress
MetaVia announced acceptance of a late-breaking poster on DA-1726, a once-weekly GLP-1/glucagon dual agonist, at the EASL Congress May 27–30 in Barcelona highlighting safety, tolerability and pharmacodynamics in the Phase 1 Part 3 titration study. The trial aims to optimize higher dose levels with data expected in Q4 2026.
1. Poster Acceptance for DA-1726
MetaVia secured a late-breaking abstract (LB26-5204, LBP-010) for a poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026, scheduled May 27–30 in Barcelona. The session will spotlight DA-1726’s safety, tolerability, pharmacokinetics and pharmacodynamics in obesity patients.
2. Phase 1 Part 3 Study Design
DA-1726 is undergoing a 16-week Phase 1 Part 3 titration study aimed at optimizing higher weekly subcutaneous doses while maintaining tolerability. Data on weight loss, glucose control and liver biomarkers are slated for release in Q4 2026.
3. Preclinical Efficacy Highlights
In preclinical mouse models, DA-1726 delivered superior weight loss compared to semaglutide and matched tirzepatide effects on food intake while preserving lean mass and improving lipid profiles. These findings underpin its best-in-class potential for obesity and MASH treatment.